Poor prep Gastrointestinal October 31, 2022 Top Line: Has anyone not been inundated with incendiary one-liners on results from the NordICC trial? The Study: Spoiler alert:…
A new PARADIGM Gastrointestinal June 9, 2022 The Japanese phase 3 PARADIGM trial analyzed 802 patients with metastatic chemo-naive RAS-wild type colon cancer receiving mFOLFOX randomized to…
Dynamic decision-making Gastrointestinal June 6, 2022 The phase 2 DYNAMIC trial demonstrates that patients with resected stage II colon cancer randomized to post-surgery circulating tumor DNA-determined…
